News

News and Press Releases
Research ICER Announces Assessment of Triple-Combination Therapy

The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The first opportunity to comment runs through Sept. 25.

| 2 min read
About the CF Foundation | Research The CF Foundation Awards Arcturus Therapeutics Up to $15M for RNA Therapy

The Cystic Fibrosis Foundation has increased its award to Arcturus Therapeutics to up to $15 million to develop a mutation-agnostic therapy for people with cystic fibrosis.

| 2 min read
Get Involved Merrill/Bank of America Raises More Than $32,000 Through Matching Gifts

To support a pair of colleagues' adoption of a baby boy, Christian, Merrill/Bank of America has raised more than $32,000 through their matching gifts program.

| 2 min read
In the Spotlight | Get Involved CF Foundation Announces 2019 Impact Grant Recipients

Recipients include five innovative programs from around the country that empower the CF community.

| 3 min read
Research | Drug Pipeline Application for Triple-Combination Therapy Submitted to the FDA

Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.

| 1 min read
Advocacy Rep. Mark Amodei Announced as New Co-Chair of Congressional CF Caucus

U.S. Rep. Mark Amodei of Nevada will join fellow Rep. Jim McGovern and Sens. Chuck Grassley and Ed Markey in co-chairing the Congressional Cystic Fibrosis Caucus, championing awareness of the rare disease and the Cystic Fibrosis Foundation's search for a cure.

| 3 min read
Advocacy Nearly 200 Volunteers Advocate for Loved Ones During 11th Annual Teen Advocacy Day

Nearly 200 people from across the country -- including teens from 38 states -- came to Washington, D.C., on June 27 to advocate for the needs of their loved ones living with cystic fibrosis during the Cystic Fibrosis Foundation's 11th Annual Teen Advocacy Day.

| 3 min read
Research | Drug Pipeline Vertex Selects Triple Combination With VX-445 to Submit for FDA Approval

Vertex Pharmaceuticals Inc. today announced that it will pursue FDA approval for the triple-combination therapy VX-445 (elexacaftor) plus tezacaftor/ivacaftor (Symdeko®).

| 3 min read
About the CF Foundation Preston W. Campbell, MD, President and CEO to Retire; Michael P. Boyle, MD, Appointed as Successor

Preston W. Campbell, III, President and CEO to retire; Michael P. Boyle, MD, appointed as successor effective January 2020.

| 4 min read
Research | Drug Pipeline FDA Approves Kalydeco for Infants With CF

The U.S. Food and Drug Administration has approved the use of ivacaftor (Kalydeco®) for children as young as 6 months.

| 2 min read